Qualidade de manga 'tommy atkins' pós-colheita com uso de cloreto de cálcio na pré-colheita Quality of 'tommy atkins' mangoes in post-harvest with calcium choride spray use in the pre-harvest period

Mangas da cultivar Tommy Atkins produzidas em Livramento de Nossa Senhora, Bahia, foram analisadas com o objetivo de verificar a influência da aplicação pré-colheita de cloreto de cálcio na vida útil pós-colheita e em relação ao distúrbio fisiológico. As pulverizações de CaC1(2) foram realizadas em três épocas: 35; 65 e 95 dias após o florescimento. Os tratamentos foram concentrações de cloreto de cálcio: 0,0%; 2,0%; 3,5%; 5,0% e 6,5%. Frutos foram colhidos, transportados para o Laboratório de Biotecnologia da UESB, armazenados em câmara fria a 10ºC e 90% UR e avaliados por período de 35 dias. O delineamento experimental foi o inteiramente casualizado, em esquema fatorial 5 x 6 (concentração x tempo de armazenamento), com 3 repetições e 2 frutos por parcela. Os parâmetros analisados foram: perda de massa, firmeza, acidez titulável, pH, sólidos solúveis, relação sólidos solúveis/acidez, incidência e severidade de colapso interno. Durante o período de armazenamento, observou-se que, a partir do 28º dia de armazenamento, a perda de massa dos frutos foi menor em doses maiores de cloreto de cálcio. A firmeza e o teor de sólidos solúveis foram influenciados em maiores concentrações de CaC1(2), enquanto as demais características não foram influenciadas significativamente. A incidência e a severidade do colapso interno dos frutos não foram afetadas com uso de cloreto de cálcio. Verificou-se que a aplicação pré-colheita de cloreto de cálcio, em doses maiores (> 3,5%), aumenta a vida útil pós-colheita da manga, contudo não reduz a incidência do colapso interno.<br>The fruits produced in Livramento de Nossa Senhora, Bahia, had been analyzed with the objective to verify the influence of spraying application of calcium chloride in pre-harvest period on shelf life of 'Tommy Atkins' mangoes. The sprayings of CaC1(2) were made three times: 35, 65 and 95 days after mango flowering. The used treatments were composed of the following concentrations of calcium chloride: 0.0%; 2.0%; 3.5%; 5.0% and 6.5%. The fruits were harvested, transported to the Laboratory of Biotechnology of Bahia Southwest State University, stored at 10ºC and 90% RH and evaluated during 35 days. The statistical design was an entirely randomized, using a factorial scheme 5 x 6, with 3 repetitions and 2 fruits/plot. The analyzed parameters were: loss of mass, firmness, titratable acidity, pH, soluble solids, soluble solids and titratable acidity ratio, incidence and severity of internal breakdown. During the period of fruit storage it was observed that in relation to the loss of mass, the fruits presented inferior loss when higher concentration of calcium chloride were used, from the 28th day of storage. For soluble solids and firmness they were also influenced in higher concentrations. For the other characteristics no differences were observed among them. No effects were verified in incidence and severity of internal breakdown in mangoes. From the results it can be concluded that the application of high concentrations of calcium chloride (>3,5%) in mango tree in pre-harvest period, increase shelf-life after 28 days of fruit storage, however it does not reduce the incidence of internal breakdown

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit